96449-69-3

Usage

Uses

Used in Pharmaceutical Development:
1-Benzyl-4-(hydroxymethyl)pyrrolidin-2-one is used as a pharmaceutical candidate for the development of new drugs due to its unique structure and properties. Its potential applications in medicine could be vast, depending on further research into its pharmacological effects.
Used in Organic Synthesis:
In the field of organic synthesis, 1-Benzyl-4-(hydroxymethyl)pyrrolidin-2-one is used as a building block. Its specific functional groups and structural features make it a versatile component in the creation of more complex organic molecules.
Used in Medicinal Chemistry Research:
1-Benzyl-4-(hydroxymethyl)pyrrolidin-2-one is utilized in research settings to study its effects and potential uses in medicinal chemistry. This research can provide insights into its interactions with biological systems and its potential role in the treatment of various conditions.

InChI:InChI=1/C12H15NO2/c14-9-11-6-12(15)13(8-11)7-10-4-2-1-3-5-10/h1-5,11,14H,6-9H2

Upstream product

• 51535-00-3 methyl 1-benzyl-5-oxo-3-pyrrolidinecarboxylate 
• 5733-86-8 1-benzyl-5-oxopyrrolidine-3-carboxylic acid 
• 100-46-9 benzylamine 
• 617-52-7 Dimethyl itakonate 

Downstream Products

• 85539-59-9 1-Benzyl-4-iodomethyl-pyrrolidin-2-one 
• 1225600-76-9 1-benzyl-4-(fluoromethyl)pyrrolidin-2-one 
• 1227725-28-1 (+/-)-1-benzyl-4-bromomethylpyrrolidin-2-one 
• 1412896-33-3 C₁₈H₁₇Cl₂NO₂ 
• 1412896-34-4 C₁₈H₁₅Cl₂NO₂ 
• 1373821-40-9 C₁₃H₁₇NO₄S 
• 1033718-06-7 cis-tert-butyl N-[4-(fluoromethyl)pyrrolidin-3-yl]carbamate 
• 1396762-87-0 C₂₄H₄₁NO₆Si 
• 1396762-85-8 C₂₂H₃₅NO₄Si 
• 1396762-81-4 C₁₆H₂₂N₂O₂ 
• 1396762-80-3 C₂₉H₄₂N₂O₂Si 
• 1396762-78-9 2-benzyl-4-((tert-butyldimethylsilanyl)oxymethyl)-2-aza-spiro[4.4]non-7-en-1-one 
• 1396762-76-7 3,3-diallyl-1-benzyl-4-((tert-butyldimethylsilanyl)oxymethyl)-pyrrolidin-2-one 

Relevant academic research and scientific papers

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

A Diaminopropane Diolefin Ru(0) Complex Catalyzes Hydrogenation and Dehydrogenation Reactions

New ruthenium (0) complexes with a cooperative diolefin diaminopropane (DAP) or the dehydrogenated iminopropenamide ligand (IPA) were synthesized for comparison with their diaminoethane (DAE)/ diazadiene (DAD) ruthenium analogues. These DAP/IPA complexes are efficient catalysts in dehydrogenation reactions of alkaline aqueous methanol which proceeds under mild conditions (T=70 °C) and of higher alcohols, forming the corresponding carbonate and carboxylates, respectively. The scope of the reaction includes an example of a 1,2-diol as model for biomass derived alcohols. Their catalytic applications are extended to the atom-efficient dehydrogenative coupling of alcohols and amines to amides. The reaction proceeds without any additives and is applicable to the synthesis of formamides from methanol. Moreover, DAP/IPA complexes catalyze the hydrogenation of a series of esters, lactone, ketone, activated olefin, aldehyde and imine substrates. The diaminopropane Ru catalyst exhibits higher activity compared to the dehydrogenated β-ketiminate (IPA) and previously studied DAD/DAE based catalysts. We present studies on their stoichiometric reactivity with relevance to their possible catalytic mechanisms and the isolation and full characterization of key reaction intermediates.

A method for preparing west Naira Tanzania

The invention discloses a preparation method for nebracetam, and belongs to the technical field of medical chemistry. The key points of the technical scheme of the invention are as follows: the preparation method for the nebracetam comprises the following steps: performing Michael addition reaction and intramolecular cyclization on dimethyl itaconate and benzylamine serving as raw materials to obtain 1-benzyl-5-oxopyrrolidin-3-carboxylic methyl ester; reducing the 1-benzyl-5-oxopyrrolidin-3-carboxylic methyl ester by sodium borohydride to obtain 1-benzyl-4-hydroxymethyl-pyrrolidine-2-keton; performing methyl sulfonylation on the 1-benzyl-4-hydroxymethyl-pyrrolidine-2-keton to obtain 1-benzyl-5-oxopyrrolidin-3-carboxylic methanesulfonate; finally, performing ammonification and reduction on the 1-benzyl-5-oxopyrrolidin-3-carboxylic methanesulfonate by using ammonia water to obtain the nebracetam. The preparation method is simple in preparation process, easy to control and high in target product yield, and meets the requirement for green chemistry.

Reductive Alkylation of Tertiary Lactams via Addition of Organocopper (RCu) Reagents to Thioiminium Ions

A simple procedure for the conversion of tertiary lactams to 2-monoalkylated cyclic amines is described. The reaction sequence involves conversion of a lactam to a thioiminium ion followed by reaction with an organocopper (RCu) reagent and final reduction with triacetoxyborohydride. The reaction is high yielding and shows an excellent functional group tolerance. Its utility is demonstrated by a rapid synthesis of indolizidine 167B. The excellent chemoselectivity of the process, where only monoalkylation products are formed, is rationalized by a mechanism involving the formation of a transient enamine.

Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1

Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal neurodegenerative disease. Although the cause remains unknown, misfolded protein aggregates are seen in neurons of sporadic ALS patients, and familial ALS mutations, including mutations in su

Synthesis of new β-trifluoromethyl containing GABA and β-fluoromethyl containing N-benzylpyrrolidinones

A whole series of 3-(mono-, di-, trifluoro)methyl-substituted N-benzylpyrrolidinones 5a-c was synthesized by deoxyfluorination of corresponding 3-functionalized N-benzylpyrrolidinones. New β-trifluoromethyl containing GABA 4a was obtained in two alternative ways: by successive hydrolysis and hydrogenolysis of 3-trifluoromethyl N-benzylpyrrolidinone 5a and from trifluoroacetone as starting compound.

Intramolecular 1,6-addition to 2-pyridones. Mechanism and synthetic scope

Figure presented The scope and limitations of the intramolecular 1,6-addition of an enolate to a 2-pyridone moiety, a reaction that has found application in the synthesis of the lupin alkaloids, have been probed. This nucleophilic addition process has been shown to be reversible and favored in the case of (less stabilized) amide and lactam enolates, which readily form five- and six-membered bi-/tricyclic products. Alternative enolates (ketone, ester, thiolactam) and a variety of different acceptors (isoquinolinone, pyrimidinone, pyrazinone, pyridopyrazinone) have been evaluated, and a range of competing side reactions have been identified and characterized using various techniques, including in situ IR.

PYRROLIDINE DERIVATIVE OR SALT THEREOF

[PROBLEMS] To provide a compound which can be used for the treatment of a disease associated with a calcium-sensing receptor (CaSR), particularly hyperparathyroidism. [MEANS FOR SOLVING PROBLEMS] It is found that a novel pyrrolidine derivative having an aminomethyl group substituted by an arylaklyl group or the like or a salt thereof has an excellent CaSR agonistic modulation effect and also has an excellent selectivity in the inhibition of CYP2D6 which may cause a drug-drug interaction. Thus, the novel pyrrolidine derivative is useful as a therapeutic agent for a disease associated with CaSR (e.g., hyperparathyroidism, renal osteodystrophy and hypercalcemia).

Alpha2delta ligands for fibromyalgia and other disorders

This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; and R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S, 5R)-3-Aminomethyl-5-methyl-octanoic acid

Method of treating tinnitus

The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.